AQST News and Press, Aquestive Therapeutics Inc. From 09/30/19

Aquestive Therapeutics (NASDAQ: AQST ) has completed its Phase 1 dose escalation proof-of-concept study in healthy subjects for AQST-108. More news on: Aquestive Therapeutics, Inc., Healthcare stocks news, Read more ...

- Represents Significant Proof-of-Concept Milestone for Sublingual Epinephrine Pipeline Product - WARREN, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST ), a specialty pharmaceutical company focused on developing and commercializing differentiated p...

Aquestive Therapeutics ( AQST ) continues to be on my watchlist, but it appears it might be time to pull the trigger on a buy in the near future. The company has made significant progress throughout its pipeline programs in the past few months. Most significantly, the company reported positive...

WARREN, N.J., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today announced that the ma...

Aquestive Therapeutics, Inc. (AQST) Q2 2019 Earnings Conference Call August 07, 2019 08:00 AM ET Company Participants Lauren Walrath - Head, Corporate Marketing and Communications Keith Kendall - Chief Executive Officer John Maxwell - Chief Financial Officer Gary Slatko - Senio...

Aquestive Therapeutics (NASDAQ: AQST ): Q2 GAAP EPS of -$0.82 misses by $0.18 . More news on: Aquestive Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Reported positive topline data from single dose crossover pharmacokinetic (PK) trial for Libervant™ (diazepam) Buccal Film and expects to complete its rolling New Drug Application (NDA) submission in fourth quarter 2019 Reported a 250% increase in Sympazan ® shipments compar...

The study confirms the dosing algorithm developed for Libervant (diazepam) buccal film, a potentially first in class oral treatment for breakthrough or cluster seizures Libervant adult rolling New Drug Application (NDA) submission expected to be completed in the fourth quarter of 2019 ...

WARREN, N.J., July 29, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today announced that manage...

WARREN, N.J. , July 18, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products based on its proprietary PharmFilm ® technology to meet patients' unmet needs and solve ...